Wong Yung-Hao, Lin Chih-Lung, Chen Ting-Shou, Chen Chien-An, Jiang Pei-Shin, Lai Yi-Hua, Chu Lichieh, Li Cheng-Wei, Chen Jeremy J W, Chen Bor-Sen
BMC Med Genomics. 2015;8 Suppl 4(Suppl 4):S4. doi: 10.1186/1755-8794-8-S4-S4. Epub 2015 Dec 9.
Computer-aided drug design has a long history of being applied to discover new molecules to treat various cancers, but it has always been focused on single targets. The development of systems biology has let scientists reveal more hidden mechanisms of cancers, but attempts to apply systems biology to cancer therapies remain at preliminary stages. Our lab has successfully developed various systems biology models for several cancers. Based on these achievements, we present the first attempt to combine multiple-target therapy with systems biology.
In our previous study, we identified 28 significant proteins--i.e., common core network markers--of four types of cancers as house-keeping proteins of these cancers. In this study, we ranked these proteins by summing their carcinogenesis relevance values (CRVs) across the four cancers, and then performed docking and pharmacophore modeling to do virtual screening on the NCI database for anti-cancer drugs. We also performed pathway analysis on these proteins using Panther and MetaCore to reveal more mechanisms of these cancer house-keeping proteins.
We designed several approaches to discover targets for multiple-target cocktail therapies. In the first one, we identified the top 20 drugs for each of the 28 cancer house-keeping proteins, and analyzed the docking pose to further understand the interaction mechanisms of these drugs. After screening for duplicates, we found that 13 of these drugs could target 11 proteins simultaneously. In the second approach, we chose the top 5 proteins with the highest summed CRVs and used them as the drug targets. We built a pharmacophore and applied it to do virtual screening against the Life-Chemical library for anti-cancer drugs. Based on these results, wet-lab bio-scientists could freely investigate combinations of these drugs for multiple-target therapy for cancers, in contrast to the traditional single target therapy.
Combination of systems biology with computer-aided drug design could help us develop novel drug cocktails with multiple targets. We believe this will enhance the efficiency of therapeutic practice and lead to new directions for cancer therapy.
计算机辅助药物设计在发现治疗各种癌症的新分子方面有着悠久的历史,但一直专注于单一靶点。系统生物学的发展使科学家们能够揭示更多癌症的隐藏机制,但将系统生物学应用于癌症治疗的尝试仍处于初步阶段。我们的实验室已成功为多种癌症开发了各种系统生物学模型。基于这些成果,我们首次尝试将多靶点治疗与系统生物学相结合。
在我们之前的研究中,我们确定了四种癌症的28种重要蛋白质,即共同核心网络标志物,作为这些癌症的管家蛋白。在本研究中,我们通过对这四种癌症的致癌相关性值(CRV)求和对这些蛋白质进行排名,然后进行对接和药效团建模,以便在NCI数据库中对抗癌药物进行虚拟筛选。我们还使用Panther和MetaCore对这些蛋白质进行通路分析,以揭示这些癌症管家蛋白的更多机制。
我们设计了几种方法来发现多靶点联合疗法的靶点。在第一种方法中,我们为28种癌症管家蛋白中的每一种确定了前20种药物,并分析对接姿态以进一步了解这些药物的相互作用机制。在筛选重复项后,我们发现其中13种药物可以同时靶向11种蛋白质。在第二种方法中,我们选择了CRV总和最高的前5种蛋白质,并将它们用作药物靶点。我们构建了一个药效团,并将其应用于针对Life-Chemical文库进行抗癌药物的虚拟筛选。基于这些结果,与传统的单一靶点治疗相比,湿实验室生物科学家可以自由研究这些药物的组合用于癌症的多靶点治疗。
系统生物学与计算机辅助药物设计的结合可以帮助我们开发具有多个靶点的新型药物组合。我们相信这将提高治疗实践的效率,并为癌症治疗带来新的方向。